EANS-Adhoc: Sygnis Pharma AG / SYGNIS secures up to EUR 10 Million through a 3 year Standby Equity Distribution Agreement with Yorkville

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Company Information

19.10.2009

Heidelberg, 19 October 2009 - SYGNIS Pharma AG (Frankfurt: LIO; ISIN
DE0005043509; Prime Standard), a clinical stage biotech company
developing innovative CNS treatments, today announced that it has
entered into a 3 year standby equity distribution agreement (SEDA)
with YA Global Master SPV LTD (YA Global).

The agreement provides SYGNIS with the option to request YA Global,
during the next 36 months, to subscribe for newly issued SYGNIS
shares, from the company´s authorized capital, in tranches of up to
EUR 500,000 each. The subscription price of the new shares will be
determined at 95% of the lowest volume-weighted average price of one
of the five trading days following the date of the relevant draw down
notice.

The total value of this equity facility aggregates to up to EUR 10
million, provided that the aggregate number of shares issued to YA
Global shall not exceed 9,9% of SYGNIS´ share capital. YA Global can
either accumulate these shares or place them in the market. However,
YA Global is committed not to short sell or enter into any hedging
transactions related to particular company stock.

### Disclaimer Some statements included in this press release,
relating neither to proven financial results nor other historical
data, should be viewed as forward-looking, i.e. not definite. Such
statements are mainly predictions of future results, trends, plans or
goals. These statements should not be considered to be total
guarantees since given their very nature they are subject to known
and unknown risks and imponderability and can be affected by other
factors as a consequence of which the actual results, plans and goals
of SYGNIS Pharma AG may deviate greatly from the established
conclusions or implied predictions contained in such statements.
SYGNIS does not undertake to publicly update or revise these
statements in the light of new information or future results or for
any other reason. ###

Ende der Mitteilung euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: SYGNIS Pharma AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Dr. Franz-Werner Haas

VP Operations / General Counsel

Tel: +49 (0) 6221-454 812

Email: franz-werner.haas@sygnis.de

Branche: Biotechnology
ISIN: DE0005043509
WKN: 504350
Index: CDAX
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade